[go: up one dir, main page]

WO2010087980A3 - Bicyclic amide derivatives for the treatment of respiratory depression - Google Patents

Bicyclic amide derivatives for the treatment of respiratory depression Download PDF

Info

Publication number
WO2010087980A3
WO2010087980A3 PCT/US2010/000254 US2010000254W WO2010087980A3 WO 2010087980 A3 WO2010087980 A3 WO 2010087980A3 US 2010000254 W US2010000254 W US 2010000254W WO 2010087980 A3 WO2010087980 A3 WO 2010087980A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bicyclic amide
amide derivatives
respiratory depression
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000254
Other languages
French (fr)
Other versions
WO2010087980A2 (en
Inventor
Rudolf Mueller
Leslie J. Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Publication of WO2010087980A2 publication Critical patent/WO2010087980A2/en
Publication of WO2010087980A3 publication Critical patent/WO2010087980A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
PCT/US2010/000254 2009-02-02 2010-01-29 Bicyclic amide derivatives for the treatment of respiratory depression Ceased WO2010087980A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
US61/206,642 2009-02-02

Publications (2)

Publication Number Publication Date
WO2010087980A2 WO2010087980A2 (en) 2010-08-05
WO2010087980A3 true WO2010087980A3 (en) 2011-02-24

Family

ID=42396261

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/000254 Ceased WO2010087980A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for the treatment of respiratory depression
PCT/US2010/000255 Ceased WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000255 Ceased WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Country Status (12)

Country Link
EP (1) EP2391621A4 (en)
JP (1) JP2012516845A (en)
KR (1) KR20110115139A (en)
CN (1) CN102369201A (en)
AU (1) AU2010208646A1 (en)
BR (1) BRPI1005316A2 (en)
CA (1) CA2751285A1 (en)
EA (1) EA018994B1 (en)
IL (1) IL214392A0 (en)
MX (1) MX2011008060A (en)
SG (1) SG173168A1 (en)
WO (2) WO2010087980A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055508A1 (en) * 1997-02-13 2002-05-09 Cortex Pharmaceuticals, Inc. Benzofurazan compounds which enhance AMPA receptor activity
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331761T2 (en) * 1992-07-24 2002-09-12 The Regents Of The University Of California, Oakland MEDICINAL PRODUCTS THAT INCREASE SYNAPTIC RESPONS BROUGHT BY AMPA RECEPTORS
PT1026950E (en) * 1997-10-27 2006-06-30 Cortex Pharma Inc TREATMENT OF SCHIZOPHRENIA WITH AMPAKINS AND NEUROLEPTICS
AU2008254960B2 (en) * 2007-05-17 2014-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
NZ583823A (en) * 2007-08-10 2011-07-29 Cortex Pharma Inc Furazanes for enhancing glutamatergic synaptic responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US20020055508A1 (en) * 1997-02-13 2002-05-09 Cortex Pharmaceuticals, Inc. Benzofurazan compounds which enhance AMPA receptor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUN REN ET AL.: "Ampakines alleviate respiratory depression in rats", AM. J. CRIT. CARE MED., vol. 174, 2006, pages 1384 - 1391 *

Also Published As

Publication number Publication date
EP2391621A2 (en) 2011-12-07
EA018994B1 (en) 2013-12-30
IL214392A0 (en) 2011-09-27
AU2010208646A1 (en) 2011-09-01
CN102369201A (en) 2012-03-07
SG173168A1 (en) 2011-08-29
MX2011008060A (en) 2011-09-09
WO2010087981A3 (en) 2011-03-24
JP2012516845A (en) 2012-07-26
WO2010087980A2 (en) 2010-08-05
EP2391621A4 (en) 2012-07-25
BRPI1005316A2 (en) 2019-09-24
EA201101162A1 (en) 2012-01-30
KR20110115139A (en) 2011-10-20
CA2751285A1 (en) 2010-08-05
WO2010087981A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
HRP20130539T1 (en) Pharmaceutical dosage forms
WO2007142755A3 (en) Purine analogs
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2009121039A3 (en) Administration of benzodiazepine compositions
IN2014DN09805A (en)
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
EP1986639A4 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
WO2010054113A3 (en) Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
IN2012DN00971A (en)
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
WO2012174158A3 (en) Administration of benzodiazepine
WO2012015758A3 (en) Methods of treating pain
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX342257B (en) Oxaspiro [2.5] octane derivatives and analogs.
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2008131946A3 (en) Substituted amide derivatives
WO2010129048A3 (en) Therapeutic compounds
MX357556B (en) Aqueous compositions comprising arbekacin.
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
PL2379066T3 (en) Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736149

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10736149

Country of ref document: EP

Kind code of ref document: A2